Sugi Predict

Sugi Predict / Compounds / SCHEMBL1344016

SCHEMBL1344016

SCHEMBL1344016

CC(C)CCCOC(=O)C=CC#N

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.44
▸ HCAR2 Q8TDS4 4/20 0.40
▸ TDP1 Q9NUW8 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ ESR1 P03372 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ TSHR P16473 3/20 0.34
▸ HPGD P15428 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ PTPN1 P18031 1/20 0.33
▸ BLM P54132 1/20 0.31
▸ ZDHHC20 Q5W0Z9 1/20 0.31
▸ ZDHHC2 Q9UIJ5 1/20 0.31
▸ APP P05067 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5580247 0.93 HCAR2 (0.42) ATMHCAR2TDP1LMNAESR1
SCHEMBL4621786 0.93 HCAR2 (0.42) ATMHCAR2TDP1LMNAESR1
SCHEMBL1603097 0.89 TDP1 (0.48) ATMHCAR2TDP1LMNATSHR
SCHEMBL11748614 0.85 ATM (0.59) ATMHCAR2TDP1LMNAESR1
SCHEMBL6903301 0.85 ATM (0.59) ATMHCAR2TDP1LMNAESR1
SCHEMBL6903305 0.85 ATM (0.59) ATMHCAR2TDP1LMNAESR1
SCHEMBL6453889 0.82 ATM (0.55) ATMHCAR2TDP1LMNAESR1
SCHEMBL24797 0.80 ATM (0.70) ATMHCAR2MAPTRAB9ANPSR1
SCHEMBL4967675 0.80 ATM (0.48) ATMHCAR2TDP1LMNAESR1
SCHEMBL4967684 0.80 ATM (0.48) ATMHCAR2TDP1LMNAESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119233828-A Nano encapsulated pharmaceutical composition and use thereof 福君基因公司 2024-12-31 — — CN claimed
CN-119212725-A Polymer nano aggregate pharmaceutical composition and application thereof ANP科技公司 2024-12-27 — — CN claimed
CN-113840594-A Poly (alkyl cyanoacrylate) nanoparticles for the treatment of cancer 新泰福托特股份有限公司 2021-12-24 — — CN claimed
US-10967039-B2 Process for preparing stealth nanoparticles SINTEF TTO AS (NO) 2021-04-06 — — US claimed
EP-3004183-B1 PROCESS FOR PREPARING STEALTH NANOPARTICLES SINTEF TTO AS (NO) 2017-07-05 — — EP claimed
US-20160129132-A1 Process for Preparing Stealth Nanoparticles SINVENT AS (NO) 2016-05-12 — — US claimed
EP-3004183-A1 PROCESS FOR PREPARING STEALTH NANOPARTICLES Sintef TTO AS (NO) 2016-04-13 — — EP claimed
WO-2014191502-A1 PROCESS FOR PREPARING STEALTH NANOPARTICLES SINVENT AS (NO) 2014-12-04 — — WO claimed
WO-2013129722-A1 TISSUE ADHESIVE FOR WOUND CLOSURE AND PREPARATION METHOD THEREOF GENEWEL CO., LTD (KR) 2013-09-06 — — WO claimed
US-20040028635-A1 Block-structure copolymer consisting of a saccharide segment bound to at least a biodegradable hydrophobic segment, and corresponding particles CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) 2004-02-12 — — US claimed
CN-122029277-A Engineered class 2V-type CRISPR system 斯克里贝治疗公司 2026-05-12 — — CN disclosed
US-12594349-B2 Compositions and methods for the targeting of PCSK9 SCRIBE THERAPEUTICS INC. (US) 2026-04-07 — — US disclosed
US-12551573-B2 Compositions and methods for the targeting of PCSK9 SCRIBE THERAPEUTICS INC. (US) 2026-02-17 — — US disclosed
EP-4689115-A1 REPRESSOR FUSION PROTEIN SYSTEMS Scribe Therapeutics Inc. (US) 2026-02-11 — — EP disclosed
EP-4689082-A1 COMPOSITIONS AND METHODS FOR THE TARGETING OF PCSK9 Scribe Therapeutics Inc. (US) 2026-02-11 — — EP disclosed
US-20010034333-A1 Cyclodextrin polymer compositions for use as drug carriers KOSAK KENNETH M (US) 2001-10-25 — — US disclosed
US-20010021703-A1 Biocleavable micelle compositions for use as drug carriers KK BIOMED CORPORATION 2001-09-13 — — US disclosed
WO-2000040962-A1 CYCLODEXTRIN POLYMERS FOR USE AS DRUG CARRIERS KOSAK KEN M (US) 2000-07-13 — — WO disclosed
CN-1121725-A Carrying anti-CD4Immunoparticles of monoclonal antibodies and their use for the prevention and/or treatment of HIV infectionPathogenic conditions or use as biologics UNION PHARMA SCIENT APPL (FR) 1996-05-01 — — CN disclosed
US-4844900-A ALKYL CYANOACRYLATE POLYMERS N.V. SOPAR S.A. (BE) 1989-07-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034333-A1 Cyclodextrin polymer compositions for use as drug carriers ABCB1, ABCG2, CTTN ATM 3687/4885HCAR2 2545/4885TDP1 1366/4885
US-12594349-B2 Compositions and methods for the targeting of PCSK9 PCSK9, ZFR, ZFX ATM 1650/4885HCAR2 4720/4885TDP1 38/4885
US-20040028635-A1 Block-structure copolymer consisting of a saccharide segment bound to at least a biodegradable hydrophobic segment, and corresponding particles MSR1, CBR1, GRHPR ATM 4196/4885HCAR2 15/4885TDP1 3557/4885
US-12551573-B2 Compositions and methods for the targeting of PCSK9 PCSK9, ZFR, ZFX ATM 2964/4885HCAR2 4640/4885TDP1 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.